Skip to main content

MOTS-c vs 5-Amino-1MQ

Both MOTS-c and 5-Amino-1MQ are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

5-Amino-1MQ

Evidence C+

5-Amino-1-Methylquinolinium

A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.

View full 5-Amino-1MQ profile →

Side-by-Side

AttributeMOTS-c5-Amino-1MQ
Evidence GradeBC+
FDA StatusNot FDA-approved — research peptide; multiple early-phase clinical trialsNot FDA-approved — small-molecule research compound (NNMT inhibitor)
Typical Dose5–10 mg, 2–3 times weekly (subcutaneous)50–150 mg orally daily (research-only)
Clinics Indexed2231
Categoriesmetabolic, longevityfat-loss, longevity

Key reported benefits — MOTS-c

  • Insulin sensitivity
  • Exercise capacity
  • Metabolic flexibility

Key reported benefits — 5-Amino-1MQ

  • NNMT inhibition
  • Fat-mass reduction (preclinical)
  • Muscle stem-cell support

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons